Pyxis Oncology, Inc.: 10% owner GordonMD Global bought 7,172,000 shares

What happened

• GordonMD Global Investments LP, reported as a 10% owner, acquired 7,172,000 derivative securities (reported as a purchase) on Oct 1, 2026. The transaction line shows price and total value as not reported. Footnote F2 states a combined public offering price of $2.90 per share and accompanying Common Stock Purchase Warrant.

Key details

• Transaction date and code: Oct 1, 2026; code P (purchase).
• Price reported in transaction: N/A; filing footnote F2: combined public offering price $2.90 per share and accompanying warrant.
• Instrument and terms from footnotes:
  • Footnote F2: combined public offering price $2.90 for each share and accompanying Common Stock Purchase Warrant.
  • Footnote F3: warrant exercise price $3.50, subject to adjustments in the warrant.
  • Footnote F4: warrant not exercisable unless issuer stockholders approve and the Charter Amendment becomes effective.
  • Footnote F5: warrant expiration is the earlier of (i) five years after the Charter Amendment Effective Date and (ii) 30 days after the later of the Charter Amendment Effective Date and public disclosure of the overall survival analysis results for a specified Phase 1 study.
• Ownership and structure (footnote F1): the securities are held directly by GordonMD Long Biased Master Fund LP; GordonMD Global Investments LP is the investment manager of the Master Fund; Craig D. Gordon is managing member of the GP; each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership except to the extent of any pecuniary interest.
• Filing status: this is an amended Form 4/A filed Oct 9, 2026 to correct the number of Common Stock Purchase Warrants reported in the Form 4 filed Oct 2, 2026. The transaction reported occurred on Oct 1, 2026.
• Shares owned following the transaction: not specified in this filing.

Why it may matter

• The filing reports an acquisition of derivative securities (Common Stock Purchase Warrants) rather than a simple market trade of common stock; the warrants have an exercise price of $3.50 and are subject to exercisability and expiration conditions in the footnotes.
• The reporting party is a 10% owner and an investment manager of the Master Fund, not an individual executive.
• This filing does not show why the insider traded or why the company acted.